✨
AI Summary
- New GLP-1 drugs like Ozempic show significant weight loss potential beyond diabetes.
- Pharmaceutical companies Novo Nordisk and Eli Lilly see stock surges.
- James van Geelen explores the broad economic impact of these new medications.